Converge Bio is a Boston- and Tel Aviv-based startup founded in 2023 that builds a generative AI lab for the life sciences. Its platform provides a library of foundation models spanning all biological languages, DNA, RNA, protein sequences, and small molecules, that pharma and biotech teams can fine-tune for specific tasks using Converge's data-enrichment pipeline. The system supports antibody design, screening, and optimization, including de novo design, affinity maturation, and humanization, as well as expression optimization across CHO, HEK293, E. coli, and other systems. Converge positions itself to make generative AI drug discovery accessible to every biotech rather than only those with in-house ML teams. By early 2026 it had completed over 40 programs with more than a dozen pharmaceutical and biotech customers and grown its team rapidly. It raised a $25M Series A led by Bessemer Venture Partners.